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Reply to Volcik et al.
To the Editor:
Volcik et al. (2001 [in this issue]) provide support-
ing evidence that methylenetetrahydrofolate reductase
(MTHFR) 677 and 1298 alleles have crossed over, as
we have demonstrated in fetal tissue and in antenatal
subjects (Isotalo et al. 2000). Their observations also
support the findings of Hanson et al. (2001), who dem-
onstrated, in a study of adults, a genotype frequency of
0.2% for both MTHFR 677CT/1298CC and MTHFR
677TT/1298AC. The only MTHFR crossover combi-
nation that we observed in an antenatal control group
was 677TT/1298AC (Isotalo et. al 2000). We hypoth-
esized that the allelic combinations 677TT/1298CC and
677CT/1298CC are potentially deleterious or lethal in
utero; however, the existence of 677CT/1298CC in both
adults and children with spina bifida (SB) casts some
doubt on our hypothesis.
A major consideration not addressed by Volcik et al.
(2001 [in this issue]), concerning their study group, is that
their study focused on children with SB and on their par-
ents. Children with SB have survived a fetal defect—one
that is known to cause stillbirth and miscarriage.Without
medical intervention, postgestational mortality in infants
with SB is high. Therefore, the MTHFR genotype com-
binations and frequencies observed in the nonviable group
that we studied may overlap with those in groups with SB.
Additionally, development of SB, as well as of other
neural-tube defects, can be reduced by folate sufficiency
and therefore is affected by diet and, possibly, by other
defects within the folate-delivery andmetabolic pathways.
Folate status has been shown to affect the contribution
of the MTHFR 677 genotype to SB (Christensen et al.
1999). Nutritional-status differences between the study
groups may influence the survival of specific genotypes.
The contribution that the mother makes to SB or to fetal
demise may be, in part, genetic—as was possibly the case
in the U.S. 677TT/1298AC representation—and most
certainly is in part due to maternal folate sufficiency. The
distribution of 677TT/1298AC combined genotypes was
well represented in all children with SB and in Hispanic
parents but not in U.S. parents. Notably, the only groups
with a strong representation of 677CT/1298CC, relative
to the 677TT/1298AC genotype, were the U.S. and Ca-
nadian mothers of children with SB. This is in contrast
to the lack of 677CT/1298CC in our Canadian antenatal
control group. Of 148 control subjects, Volcik et al. found
2 individuals with the 677CT/1298CC genotype.
Volcik et al.’s Canadian study group consisted of af-
fected families with SB and did not contain controls;
therefore, we find it difficult, in relation to our control
group, to draw conclusions concerning their findings of
the 677CT/1298CC combinations. Our Canadian group
was predominantly of European (Celtic) descent, al-
though some Canadians of other derivations were in-
cluded. It is interesting to note thatWeisberg et al. (1998)
also studied a Canadian population of children with SB
and their mothers and did not identify any individuals
with the 677CT/1298CC or 677TT/1298CC genotypes.
We still hypothesize that combined common poly-
morphisms of MTHFR play a role in fetal demise and
in the development of neural-tube defects. Maternal
MTHFR is in the position to affect the quantity and
form of folate delivered to the fetus, whereas fetal
MTHFR may subsequently affect the utilization and dis-
tribution of the supplied folate. The most important de-
terminant for the development of neural-tube defects,
however, is likely the initial folate sufficiency of the
mother. It is unfortunate that Volcik et al. did not ex-
amine patterns between the parental—in particular, the
maternal—MTHFR genotypes and the genotypes of the
children with SB that they studied. Perhaps there are
specific maternal/fetal combinations of MTHFR that
have a relationship with either fetal demise or the de-
velopment of SB.
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